Nonetheless, the lack of safety problems seen in this study should encourage further studies of fenobam, starting at low doses and with careful titration based on efficacy and tolerability, in patients with FXS—given the remarkable benefits of mGluR5 negative modulators with respect to behaviour, cognition and even dendritic structure in animal models of FXS. This evidence concerns the gene GRM5 and fragile X syndrome.